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February 2016 Abstracts S51The Ontario Clinical Oncology Group (OCOG) – ALMERA
trial (NCT02186847) is a Canadian multicenter ran-
domized phase II trial funded by the Canadian Institute
for Health Research, which is designed to examine
whether metformin has chemo-radio-sensitization ac-
tivity as well as activity as a single agent in advanced
localized NSCLC. A total of 94 patients will be random-
ized in this screening trial to standard CRT with or
without treatment with 2000mg of metformin, which is
delivered during CRT (2 cycles of cisplatin based
chemotherapy, concurrent with chest RT of 63 Gy in 30
fractions) but continues also as a single agent for a total
of 12 months.
ALMERA is designed to detect a 20% improvement in
lung cancer progression free survival at 12 months. This
trial is now open in several centers across Canada. The
primary outcome is 12 month Progression Free Survival
(PFS) and secondary outcomes include 1 and 2 y overall
survival (OAS), time to loco-regional progression, distant
progression free survival, adverse events and collection of
biospecimens for biomarker studies. These will involve
investigation of circulating serum and blood cell bio-
markers of metformin activity and tumor biomarkers such
as tumor histology, TP53, LKB1 and K-Rasmutation status.
When completed ALMERAwill provide some of the ﬁrst
prospective evidence on the potential of metformin to
improve the outcomes of standard cytotoxic therapy in
locally advanced NSCLC. Biospecimen collect will allow us
to investigate serum and tumors biomarkers ofmetformin
response. Comparison of the results of ALMERA with
other studies, like NRG-LU001, may be able to provide
evidence on the value of metformin as maintenance
therapy and assist in the design of future phase III trials
with metformin in the setting of locally advanced NSCLC.* Due to unforeseen circumstance, this poster was not presented.An integrative cross-tumors approach
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Nuremberg, Erlangen, GermanyThe KRAS oncogene represents a clinically-relevant
target in human cancers refractory to current thera-
pies. Thus, the identiﬁcation of molecules mediating
oncogenic KRAS effects may help implement novel
therapeutic strategies. Here we describe a new
approach integrating a cross-tumors gene-expression
screen and patient survival information to unveil KRAS
dependencies in human tumors. This strategy uncov-
ered the transcription factor FOS-like antigen 1
(FOSL1) as a critical mediator of KRAS-driven lung
tumors. FOSL1 was up-regulated in mouse and human
mutant KRAS cells and its high expression was a
marker of poor survival in patients harboring KRAS
mutations. Additionally, FOSL1 loss led to impaired
cell viability in mutant KRAS cancer cells in vitro and
in vivo and in a genetically-engineered mouse model of
Kras mutated lung adenocarcinoma. Mechanistically,
this effect involved the transcriptional down-regula-
tion of genes involved in mitosis, a pathway previously
postulated to act orthogonally to KRAS signaling,
whose high expression was associated with shortened
survival of mutant KRAS patients. Lastly, pharmaco-
logical inhibition of FOSL1 downstream targets
involved in mitosis progression had a preferential
deleterious impact on mutant KRAS tumors than wild
type. Collectively, our ﬁndings identify FOSL1 as a
critical factor in KRAS-driven tumors, thereby impli-
cating FOSL1 and downstream targets as potential
candidates for therapeutic intervention.
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(IASLC).Intelligent forceps for solitary
pulmonary nodule diagnostics*
Jiri Votruba, Tomas Bruha Charles University
Hospital, Praha, Czech RepublicRecently, SPNs have become more frequently encoun-
tered in pulmonary medicine. Therefore, an efﬁcient and
reliable method for detecting SPNs based on their
morphological characteristics is needed.
We have validated the efﬁcacy of near infrared (NIR)
spectroscopy based catheter connected to biopsy forceps
for solitary pulmonary nodule (SPN) diagnostics.
Methods: Between May 2014 and May 2015 we exam-
ined 20 male and 18 female patients having a median
age of 62 years with positron emission tomography-
computed tomography ﬁndings of metabolically active
SPN between 1, 5 to 3 cm in diameter.
Fluoroscopic guidance was combined with a radial
EBUS (without guide-sheath). In the case radial EBUS
